Recent research on bilirubin, a historically well-known waste product of heme catabolism, suggests an entirely new function as a metabolic hormone that drives gene transcription by nuclear receptors. Studies are now revealing that low plasma bilirubin levels, defined as “hypobilirubinemia,” are a possible new pathology analogous to the other end of the spectrum of extreme hyperbilirubinemia seen in patients with jaundice and liver dysfunction. Hypobilirubinemia is most commonly seen in patients with metabolic dysfunction, which may lead to cardiovascular complications and possibly stroke. We address the clinical significance of low bilirubin levels. A better understanding of bilirubin’s hormonal function may explain why hypobilirubinemia might be deleterious. We present mechanisms by which bilirubin may be protective at mildly elevated levels and research directions that could generate treatment possibilities for patients with hypobilirubinemia, such as targeting of pathways that regulate its production or turnover or the newly designed bilirubin nanoparticles. Our review here calls for a shift in the perspective of an old molecule that could benefit millions of patients with hypobilirubinemia.
|Journal||American Journal of Physiology - Endocrinology and Metabolism|
|State||Published - Feb 2021|
Bibliographical noteFunding Information:
This work was supported by the National Institutes of Health 1R01DK121797 (to T.D.H.) and 1R01DK126884 (to D.E.S.), the National Heart, Lung and Blood Institute K01HL125445 (to T.D.H.) and P01HL05197 (to D.E.S.), and the National Institute of General Medical Sciences P20GM104357 (to D.E.S.).
© 2021 American Physiological Society. All rights reserved.
- Bilirubin nanoparticles
- Heme oxygenase
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Physiology (medical)